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Key Points
• First description of
a patient with a germ-
line GATA2 mutation
and diagnosis of pri-
mary myelofibrosis.
•Development of bone
marrow failure on a Ja-
nus kinase inhibitor.
Introduction
The human GATA2 gene is located on the long arm of chromosome 3 (3q21.3) and contains 6 to 7
exons.1 Together with GATA1 and GATA3, it is primarily expressed in hematopoietic cells and is
a master regulator of early hematopoiesis.2-8
Mutations in GATA2 can be either inherited or acquired. The GATA2-deficiency syndrome was first
described as an autosomal-dominant immunodeficiency and bone marrow (BM) failure disorder caused
by heterozygous loss-of-function mutations inGATA2.9-15 It is also an established cause of familial forms
of acute myeloid leukemia (AML) and myelodysplastic syndrome.14 Furthermore, it is associated with an
increased risk of chronic myelomonocytic leukemia.16 In patients with GATA2 deficiency, the BM
examination typically reveals hypocellularity with a severe decrease of hematogones, monocytes, natural
killer cells, and B cells. Atypical megakaryocytes are frequently found.10,17 Recently, single-cell analysis
of GATA2-deficient patients revealed a markedly skewed differentiation pattern with expansion of the
erythroid and megakaryocytic lineage and a reduction in myeloid and lymphoid differentiation.18
AcquiredGATA2mutations are found in patients with myeloid neoplasms. In AML, somaticGATA2 gain-
of-function mutations are associated with mutations in FLT3 and NPM1 and correlate with poor
outcome.19,20 In chronic myeloid leukemia, a gain-of-function mutation in GATA2 (p.Leu359Val) was
found in 10% of cases during blast phase.21 In contrast, ,5% of patients with primary myelofibrosis
(PMF) carry somatic GATA2 mutations.22 Although GATA1 downregulation in megakaryocytes was
observed in PMF, there is no established association between GATA2-deficiency syndrome and PMF.23
Here, we describe, to our knowledge, the first case of a patient with PMF and an inherited GATA2
mutation who developed BM failure on a Janus kinase (JAK) inhibitor.
Case description
Before the diagnosis of PMF at the age of 38 years, the female patient had suffered an abortion and had
a history of human papillomavirus–positive cervical dysplasia. At diagnosis of PMF, the patient presented
with asymptomatic hepatosplenomegaly. Her complete blood count revealed mild thrombocytopenia
with normal hemoglobin and leukocyte values (Figure 1). The peripheral blood smear showed abundant
erythrocyte teardrops and leukoerythroblastosis. The lactate dehydrogenase was markedly elevated.
The BM biopsy was hypercellular, with increased inconspicuous granulopoiesis, preserved erythropoiesis,
and marked proliferation of pleomorphic megakaryocytes, with a predominance of large forms with
hyperchromatic, bulbous, and naked nuclei (Figure 2A). There were occasional small megakaryocytes with
hyposegmented nuclei as well as some large forms with multiple separated nuclei. Most of the
megakaryocytes formed clusters and sheets, frequently adjacent to bone trabeculae within dilated vascular
sinuses. A BM fibrosis grade 2 was diagnosed according toWorld Health Organization (WHO) criteria and
a JAK2-V617F mutation was detected by qualitative polymerase chain reaction. In addition, conventional
cytogenetics identified a translocation of chromosomes 3 and 12 (46,XX,t(3;12)(p21;p13)[3]/46,XX[7]).
Fluorescence in situ hybridization analysis confirmed the loss of one 39ETV6 signal (centromeric probe)
in 50 of 200 nuclei (25%). Based on the WHO 2016 classification, the diagnosis of PMF was made.
Three months after the initial diagnosis, the patient reported satiety and symptomatic splenomegaly. The
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spleen was palpable 10 cm below the left costal arch and the
myeloproliferative neoplasm (MPN) total symptom score24 was 15.
Over the next 8 months, fatigue and symptomatic splenomegaly
worsened and the patients also reported night sweats. A therapy
with the JAK inhibitor ruxolitinib was initiated and her symptoms
responded promptly (Figure 1). Six months after therapy initiation,
the spleen size was reduced to 3 to 4 cm below the left costal arch.
On therapy, the patient suffered recurrent cutaneous herpes zoster
infections. Three years after treatment initiation, PMF-associated
symptoms deteriorated and the spleen size increased, implying
resistance to ruxolitinib. Due to the lack of alternative treatment
options including allogeneic hematopoietic stem cell transplanta-
tion (allo-HSCT), which the patient declined, she remained on
a stable dose of ruxolitinib. Six years after the initial diagnosis, the
patient was diagnosed with basal cell carcinoma of the facial skin.
Coincidentally, pancytopenia with anemia grade 2, thrombocyto-
penia grade 2, and new-onset neutropenia grade 3 were diagnosed.
The dose of ruxolitinib was reduced, which led to further worsening
of the symptoms, but no improvement of the blood counts, which
continuously decreased (minimal values: hemoglobin, 68 g/L;
platelets, 38 3 109/L; neutrophils 0.23 3 109/L). A follow-up BM
examination was performed (Figure 2B). In contrast to the BM
analysis, at diagnosis 6 years prior, the cellularity was markedly
reduced, particularly myelopoiesis. Megakaryopoiesis remained
increased with typical PMF morphology. As at diagnosis, some
small and hyposegmented/monosegmented and larger multinucle-
ated forms were noted. Next-generation sequencing analysis
revealed the known JAK2-V617F mutation (variant allele frequency
[VAF], 80%) and a GATA2-N317S mutation (VAF, 48%). The
molecular analysis of the buccal swab and of the biopsy of the cervix
uteri confirmed the germline origin of the GATA2 (VAF, 51.6%
[buccal swab] and 50.0% [cervix uteri]), but not the JAK2, mutation
(VAF, 5.5% [buccal swab] and 11.8% [cervix uteri]). The diagnosis
of BM failure in the context of GATA2 deficiency was made and the
patient proceeded to allo-HSCT.
At the last follow-up, 9 months after allo-HSCT, the patient was in
a complete molecular remission with a complete donor chimerism
(.99%). The BM fibrosis was strongly reduced with only a minimal
increase of reticulin fibers.
Methods
Patient and healthy donor samples
Peripheral blood samples were collected after obtaining informed
consent.






















































































































Figure 1. Clinical and laboratory parameters. Longitudinal follow-up of myeloproliferative neoplasm total symptom score, spleen size (A), hemoglobin, platelet (B), and
neutrophil count (C).
































































































Genomic profiling was performed by using the Illumina TruSight
Myeloid, Archer VariantPlex Myeloid and FoundationOne Heme
Panels.
Flow cytometry
Mobilized peripheral blood mononuclear cells (PBMCs) from a
healthy donor (control) and PBMCs from a patient with PMF were
stained for NK cells with the following monoclonal antibodies:
Zombie Aqua Fixable Viability Kit (BioLegend), PC5.5-Conjugated
Anti-Human CD56 (clone N901; Beckman Coulter), and Pacific
Blue-Conjugated Anti-Human CD3 (clone UCHT1; Beckman
Coulter). Stained cells were analyzed on a BD LSRFortessa cell
analyzer.
Results and discussion
We retrospectively performed a targeted sequencing analysis of
genes frequently mutated in myeloid neoplasms at diagnosis and at
the BM failure stage 6 years later. The burden of the mutated JAK2
allele rose from 55% at diagnosis to 80%, whereas, as predicted,
the VAF of the GATA2 mutation remained stable (supplemental
Table 1). The increase of the mutated JAK2 allelic burden was
paralleled by an increase of the t(3;12)(p21;p13) mutated clone,
which leads to rearrangement of ETV6. ETV6 rearrangements have
been described in 0.3% of patients with MPNs, but not in PMF.25-27
The germline GATA2-N317S mutation is a missense mutation that
has previously been described in patients with myelodysplastic
syndrome and AML but not in patients with GATA2-deficiency
syndrome. Although the familial history did not reveal stigmata of
GATA2 deficiency, this patient had suffered several manifestations
of GATA2-deficiency syndrome; spontaneous abortion, recurrent
human papillomavirus, and herpes virus infections have been
reported. Also, patients with germline GATA2 mutation are at
increased risk for skin cancer, including basal cell carcinoma.
Moreover, we detected intermittent monocytopenia, but no de-
ficiency in natural killer cells (supplemental Figures 1-2).
First-degree relatives of patients with MPNs have a fivefold to
sevenfold increased risk of MPN development.28 Recently, 17
genetic risk loci for MPN development were identified, including the
previously reported JAK2 46/1 haplotype.29,30 Interestingly, 1 of
these risk loci was detected in chromosomal locus 3q21.3 and the
main single-nucleotide polymorphism (rs9864772) localized to
a distal enhancer for GATA2. In the presented case, the GATA2
mutation preceded and possibly favored the acquisition of a JAK2
mutation, which led to PMF development. Previous studies have
shown that mutations can precede the acquisition of a JAK2
mutation in MPNs.31
Cytopenias are common adverse events of ruxolitinib therapy,
particularly at the beginning of treatment. However, new-onset
grade 3/4 cytopenias after .3.5 years of treatment are unlikely to
A B
Figure 2. Comparison of BM biopsies at diagnosis and
during follow-up. (A) BM biopsy at diagnosis. (B) BM
biopsy at follow-up 6 years later. Row 1: (A) H&E stain; scale
bar, 500 mm. (B) Giemsa stain; scale bar, 1000 mm. Row
2: (A-B) Gomori methenamine silver stain; scale bar,
100 mm. Row 3: (A-B) CD61 immunohistochemistry; scale
bars, 100 mm.































































































be ruxolitinib-related.32 They may suggest transformation to AML,
which was excluded in this patient. The sudden development
of late pancytopenia in this patient is therefore likely related to
the GATA2-deficiency syndrome rather than to ruxolitinib
treatment. We therefore propose to assess germline origin in
patients with PMF and GATA2 mutations, as development of
pancytopenia in PMF patients with germline GATA2 mutations
may be indicative of BM failure. Of note, a patient with PMF
who developed aplastic BM while treated with the JAK inhibi-
tor fedratinib has previously been described, but molecular
analyses were not reported.33
In summary, we here report the first case of a patient with GATA2-
deficiency syndrome who developed PMF. The identification of
germline GATA2 mutations in PMF is of particular relevance
because patients may proceed to related donor allo-HSCT.
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